Impact of cilostazol on infrapopliteal angioplasty

Impact of Cilostazol on results of Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Lower Limb Ischemia admitted to Ahwaz Golestan hospital vascular surgery ward

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190418043306N1

Enrollment

Registered

2019-06-11

Start date

2018-03-21

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral arterial disease. Peripheral vascular disease, unspecified

Interventions

Intervention 1: Intervention group: After successful infrapopliteal angioplasty patients of this group will treat with 200 mg of cilostazol every 12 hours and 75 mg of Plavix daily for 3 months. Inter

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with Lower Limb Ischemia age over 40 years

Exclusion criteria

Exclusion criteria: Patients with congestive heart failure Patiets with previous lower exterimity endovascular therpy Patients with previous lower exterimity bypass surgery

Design outcomes

Primary

Measure	Time frame
Relief of lower extremity ischemic symptoms based on Rutherford classification. Timepoint: Documentation of lower extremity ischemic symptoms based on Rutherford classification in the beginning of trial and after 3 months of medicine consumption. Method of measurement: Measurement of severity of symptoms based on Rutherford classification.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIraj Nazari

Ahvaz University of Medical Sciences

nazari-i@ajums.ac.ir+98 61 3374 3002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026